FI3706724T3 - Suun kautta otettavia rifamysiini sv -koostumuksia - Google Patents
Suun kautta otettavia rifamysiini sv -koostumuksia Download PDFInfo
- Publication number
- FI3706724T3 FI3706724T3 FIEP18807426.4T FI18807426T FI3706724T3 FI 3706724 T3 FI3706724 T3 FI 3706724T3 FI 18807426 T FI18807426 T FI 18807426T FI 3706724 T3 FI3706724 T3 FI 3706724T3
- Authority
- FI
- Finland
- Prior art keywords
- rifamycin
- solid dosage
- pharmaceutical composition
- oral
- dosage form
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 21
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 title claims 15
- 229940109171 rifamycin sv Drugs 0.000 title claims 15
- 239000007909 solid dosage form Substances 0.000 claims 17
- HJYYPODYNSCCOU-ZDHWWVNNSA-N Rifamycin SV Natural products COC1C=COC2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C)cc(O)c4c3C2=O HJYYPODYNSCCOU-ZDHWWVNNSA-N 0.000 claims 14
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 10
- 238000004090 dissolution Methods 0.000 claims 6
- BTVYFIMKUHNOBZ-ZDHWWVNNSA-N Rifamycin S Natural products COC1C=COC2(C)Oc3c(C)c(O)c4C(=O)C(=CC(=O)c4c3C2=O)NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C BTVYFIMKUHNOBZ-ZDHWWVNNSA-N 0.000 claims 4
- BTVYFIMKUHNOBZ-ODRIEIDWSA-N Rifamycin S Chemical compound O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-ODRIEIDWSA-N 0.000 claims 4
- 239000007864 aqueous solution Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- SQTCRTQCPJICLD-KTQDUKAHSA-N rifamycin B Chemical compound OC1=C(C(O)=C2C)C3=C(OCC(O)=O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O SQTCRTQCPJICLD-KTQDUKAHSA-N 0.000 claims 4
- SQTCRTQCPJICLD-OQQFTUDCSA-N rifomycin-B Natural products COC1C=COC2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C)cc(OCC(=O)O)c4c3C2=O SQTCRTQCPJICLD-OQQFTUDCSA-N 0.000 claims 4
- 239000002702 enteric coating Substances 0.000 claims 3
- 238000009505 enteric coating Methods 0.000 claims 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 3
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 206010071061 Small intestinal bacterial overgrowth Diseases 0.000 claims 2
- 239000012062 aqueous buffer Substances 0.000 claims 2
- 239000012736 aqueous medium Substances 0.000 claims 2
- 230000007142 small intestinal bacterial overgrowth Effects 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 206010008631 Cholera Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 206010062070 Peritonitis bacterial Diseases 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 239000013583 drug formulation Substances 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 208000007386 hepatic encephalopathy Diseases 0.000 claims 1
- 150000002433 hydrophilic molecules Chemical class 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 150000002634 lipophilic molecules Chemical class 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 229940126701 oral medication Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762584226P | 2017-11-10 | 2017-11-10 | |
| PCT/IB2018/058748 WO2019092614A1 (en) | 2017-11-10 | 2018-11-07 | Oral rifamycin sv compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3706724T3 true FI3706724T3 (fi) | 2024-10-14 |
Family
ID=64426987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18807426.4T FI3706724T3 (fi) | 2017-11-10 | 2018-11-07 | Suun kautta otettavia rifamysiini sv -koostumuksia |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11564883B2 (https=) |
| EP (3) | EP4438039A3 (https=) |
| JP (2) | JP2021502382A (https=) |
| KR (1) | KR102747348B1 (https=) |
| CN (1) | CN111328279B (https=) |
| AR (1) | AR114140A1 (https=) |
| AU (1) | AU2018364617B2 (https=) |
| BR (1) | BR112020009171A2 (https=) |
| CA (1) | CA3078900A1 (https=) |
| DK (1) | DK3706724T3 (https=) |
| ES (1) | ES2989706T3 (https=) |
| FI (1) | FI3706724T3 (https=) |
| IL (1) | IL274414B2 (https=) |
| MX (1) | MX2020004706A (https=) |
| PL (1) | PL3706724T3 (https=) |
| WO (1) | WO2019092614A1 (https=) |
| ZA (1) | ZA202002726B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022102198A (ja) * | 2020-12-25 | 2022-07-07 | ライオン株式会社 | 内服固形剤 |
| US20220280478A1 (en) * | 2021-03-05 | 2022-09-08 | Bausch Health Ireland, Limited | Methods of using rifamycin sv for the treatment of sickle cell disease |
| EP4412588A1 (en) * | 2021-10-05 | 2024-08-14 | Cosmo Technologies Ltd | An in-situ gelling enema of rifamycin for treating pouchitis and distal ulcerative colitis |
| WO2025064599A1 (en) * | 2023-09-19 | 2025-03-27 | The United States Government As Represented By The Department Of Veterans Affairs | Rifamycin composition for treating sarcopenia |
| WO2025157240A1 (zh) * | 2024-01-26 | 2025-07-31 | 丹诺医药（苏州）股份有限公司 | 化合物用于制备治疗细菌代谢相关疾病的药物的用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6861053B1 (en) * | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
| CA2377301C (en) | 1999-06-14 | 2009-05-12 | Cosmo S.P.A. | Controlled release and taste masking oral pharmaceutical compositions |
| WO2005030173A1 (en) | 2003-09-25 | 2005-04-07 | Ranbaxy Laboratories Limited | Colon-specific drug delivery using interpolymer complexations |
| ITMI20041295A1 (it) | 2004-06-25 | 2004-09-25 | Cosmo Spa | Composizioni farmaceutiche antimicrobiche orali |
| KR20080081351A (ko) | 2006-01-04 | 2008-09-09 | 도꾜 메디칼 앤드 덴탈 유니버시티 | 간장 질환 치료제 및 간기능 개선제 |
| BRPI0908026B8 (pt) | 2008-02-26 | 2021-05-25 | Salix Pharmaceuticals Ltd | uso de rifaximina no tratamento de doenças do intestino |
| HRP20200284T1 (hr) | 2008-10-02 | 2020-07-10 | Salix Pharmaceuticals, Ltd. | Postupci liječenja hepatičke encefalopatije |
| US7928115B2 (en) * | 2008-10-02 | 2011-04-19 | Salix Pharmaceuticals, Ltd. | Methods of treating travelers diarrhea and hepatic encephalopathy |
| US8741048B2 (en) | 2011-08-30 | 2014-06-03 | Brother Kogyo Kabushiki Kaisha | Water-based ink for ink-jet recording and ink cartridge |
| IN2014DN06662A (https=) | 2012-02-13 | 2015-05-22 | Cosmo Technologies Ltd | |
| WO2016003536A1 (en) | 2014-06-30 | 2016-01-07 | Salix Pharmaceuticals, Inc. | Methods for retreating irritable bowel syndrome (ibs) |
| WO2017053885A1 (en) * | 2015-09-25 | 2017-03-30 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
-
2018
- 2018-11-07 EP EP24193102.1A patent/EP4438039A3/en active Pending
- 2018-11-07 EP EP24192746.6A patent/EP4431094A3/en active Pending
- 2018-11-07 JP JP2020526001A patent/JP2021502382A/ja active Pending
- 2018-11-07 PL PL18807426.4T patent/PL3706724T3/pl unknown
- 2018-11-07 CA CA3078900A patent/CA3078900A1/en active Pending
- 2018-11-07 AU AU2018364617A patent/AU2018364617B2/en active Active
- 2018-11-07 WO PCT/IB2018/058748 patent/WO2019092614A1/en not_active Ceased
- 2018-11-07 DK DK18807426.4T patent/DK3706724T3/da active
- 2018-11-07 US US16/762,760 patent/US11564883B2/en active Active
- 2018-11-07 CN CN201880072798.7A patent/CN111328279B/zh active Active
- 2018-11-07 ES ES18807426T patent/ES2989706T3/es active Active
- 2018-11-07 BR BR112020009171-5A patent/BR112020009171A2/pt unknown
- 2018-11-07 EP EP18807426.4A patent/EP3706724B1/en active Active
- 2018-11-07 IL IL274414A patent/IL274414B2/en unknown
- 2018-11-07 KR KR1020207014333A patent/KR102747348B1/ko active Active
- 2018-11-07 MX MX2020004706A patent/MX2020004706A/es unknown
- 2018-11-07 FI FIEP18807426.4T patent/FI3706724T3/fi active
- 2018-11-07 AR ARP180103244A patent/AR114140A1/es unknown
-
2020
- 2020-05-13 ZA ZA2020/02726A patent/ZA202002726B/en unknown
-
2022
- 2022-12-27 US US18/146,510 patent/US12036316B2/en active Active
-
2023
- 2023-06-21 JP JP2023101775A patent/JP7651620B2/ja active Active
-
2024
- 2024-05-30 US US18/678,539 patent/US20240398699A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3706724T3 (fi) | Suun kautta otettavia rifamysiini sv -koostumuksia | |
| JP2017528516A5 (https=) | ||
| CN111918646B (zh) | 延迟释放去铁酮片剂及其使用方法 | |
| JP2010518122A5 (https=) | ||
| JP2012533565A5 (https=) | ||
| JP2020503269A5 (https=) | ||
| JP2005528430A5 (https=) | ||
| WO2008122190A1 (en) | The composition comprising l-carnitine or derivatives thereof and its use | |
| JP2021502382A5 (https=) | ||
| WO2022098879A1 (en) | Sustained release solid dosage forms for modulating the colonic microbiome | |
| JP2008533127A5 (https=) | ||
| JP2020500864A5 (https=) | ||
| CN104379138B (zh) | 阿坎酸制剂、其使用方法及包含阿坎酸制剂的组合 | |
| JP2016505050A5 (https=) | ||
| IL272834B2 (en) | Amantadine compositions, preparations thereof, and methods of use | |
| KR20060005345A (ko) | 비-스테로이드계 항염증성 약물 투여법 | |
| KR100379155B1 (ko) | 새로운 진통제 조성물 | |
| WO2019098984A1 (en) | Synergistic combination of diclofenac, famotidine and a carbonate | |
| US11696894B2 (en) | Sequential administration of partitioned absorption aspirin or active aspirin derivative and COX-2 inhibitor | |
| HK40065231A (zh) | 延迟释放去铁酮片剂及其使用方法 | |
| HK40030435B (en) | Delayed release deferiprone tablets and methods of using the same | |
| HK40030435A (en) | Delayed release deferiprone tablets and methods of using the same | |
| RU2022106262A (ru) | Изделия и способы для введения терапевтических средств | |
| WO2014048511A1 (en) | Metadoxine for use in the treatment of liver diseases, and metadoxine extended release formulations | |
| WO2012080984A2 (es) | Comprimido farmacéutico de liberación controlada para administración oral |